Whittier Trust’s Aclaris Therapeutics ACRS Stock Holding History

Whittier Trust’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,245	Closed	-$1K	–	1512
2019 Q3	$1K	Buy	+1,245	New	+$1.77K	﹤0.01%	1417

Other funds holding ACRS

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Whittier Trust's ACRS Position: Q4 2019 in Review

Whittier Trust sold out of Aclaris Therapeutics (ACRS) in Q4 2019, closing a stake of 1,245 shares — an estimated $1K sold.

Whittier Trust first reported a position in ACRS in Q3 2019 and held it in 1 quarter. The position peaked at $1K in Q3 2019. 79 funds tracked by Wall St. Rank hold ACRS as of Q4 2019.

Whittier Trust reported no remaining Aclaris Therapeutics position as of Q4 2019 after selling out during the quarter.
Whittier Trust sold 1,245 Aclaris Therapeutics shares in Q4 2019, an estimated $1K.
Whittier Trust first reported a position in Aclaris Therapeutics in Q3 2019 and held it in 1 quarter.
Whittier Trust's Aclaris Therapeutics position peaked at $1K in Q3 2019.
79 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2019.

Based on Whittier Trust's 13F filing for Q4 2019, filed 31 Jan 2020.